Summary. The role of intracellular pancreatic B cell serotonin in the dynamics of insulin release was investigated in an in situ perfused rat pancreas preparation. Animals were pretreated with 5-hydroxytryptophan (5-HTP) to increase the intracellular levels of serotonin (5-HT) as shown by fluorescence histochemistry. Despite a clear induction of intracellular 5-HT fluorescence in pancreatic islets neither the pattern nor the total amount of insulin released were significantly modified after perfusion with either glucose or tolbutamide. However, the L-amino acid decarboxylase inhibitor, RO 4-4602, significantly decreased both phases of glucose-mediated insulin release in normal animals as well as in those receiving 5-HTP.
release caused by these serotonin antagonists has not been established and may be unrelated to their antiserotoninergic action [13, 17, 35] . In addition to this uncertainty, a conflict arises from other in vivo studies in which no inhibition of glucose-mediated insulin release was observed in either mice [28] or humans [34] pretreated with 5-HTP.
We have previously found [9, 10, 13] that serotonin, incorporated into the perfusion fluid of the in situ perfused pancreas preparation at a concentration of 1.0 X 10-SM significantly inhibited the glucosemediated first phase of insulin release but did not affect the basal release of insulin. In the present study we have evaluated the role of intracellular B cell serotonin in the dynamics of insulin release using the same in situ perfused pancreas preparation. Rat pancreases containing high levels of experimentally induced intracellular B cell serotonin, as indicated by fluorescence histochemistry [31] , were perfused with glucose or tolbutamide.
Evidence accumulated over the past few years has led to the hypothesis that intracellular B cell serotonin (5-HT) acts as a tonic inhibitor of insulin release. Serotonin is reported to inhibit glucose-mediated insulin release in vitro after administration of the precursor 5-hydroxytryptophan (5-HTP) [ 18, 26, 36, 37] . Additionally, drugs reported to be specific serotonin antagonists have been shown to potentiate the glucose-and tolbutamide-induced insulin release in adult onset diabetic patients [1, 2, 33] , acromegalic patients with glucose intolerance [4, 20] and normal subjects [30] . Similar results have been obtained in vitro using pieces of rabbit pancreas [18, 19] and in the in situ perfused rat pancreas [11] . The precise mechanism of potentiation of glucose-induced insulin
Materials and Methods
Chemica~ L-5-hydroxytyptophan (5-HTP) and the monoaminoxidase (MAO) inhibitor, nialamide, were obtained from the Sigma Chemical Company (St. Louis, Missouri, U.S.A.); Tolbutamide (Orinase R) from Upjohn (Kalamazoo, Michigan, U.S.A.); Sodium Amytal R from Eli Lilly Company (Toronto, Ontario, Canada); Kits for insulin radioimmunoassay (Phadebas R) from Pharmacia (Montreal, Quebec, Canada). The L-aromatic amino acid deearboxylase inhibitor, RO 4--4602, was a gift from Hoffman-LaRoche Limited (Vaudreuil, Quebec, Canada).
Induction of 5-HT Fluorescence in Pancreatic Islets
Serotonin within islet cells was visualized using the formaldehyde condensation technique [5] . Pancreatic biopsies were frozen in Table L Summary of experimental protocol used to assess the effect of elevated intracellular B cell serotonin on dynamics of glucose-and tolbutamide-mediated insulin release. In the glucose stimulation experiments the pancreases from four animals in each group were biopsied before and after surgery; in groups B and E the pancreases from three animals were perfused with 4.4 mmol/1 glucose; in all groups the pancreases from the remaining animals were perfused with 16.6 mmol/1 glucose. In all instances a pancreatic biopsy was taken at the end of perfusion In a previous communication [31] we have described conditions to induce accumulation of serotonin in rat pancreatic islet cells. Briefly, injection of nialamide (5 mg/kg body weight) followed by 5-HTP (50 mg/kg body weight) one hour later, resulted in intense serotonin fluorescence observed at 120 rain after injection of 5-HTP. Injection of 5-HTP alone produced similar but weaker results in terms of serotonin fluorescence.
In the present investigations we carried out pilot experiments to determine changes in serotonin fluorescence at different time intervals after 5-HTP injection. To this purpose, two groups of 12 animals each were injected intraperitoneally with either nialamide (5 mg/kg body weight) and, 60 min later, with 5-HTP (50 mg/kg body weight) or with 5-HTP alone (50 mg/kg body weight). At 15, 30, 60 and 120 min after 5-HTP injection, 3 animals from each group were anaesthetized with Na Amytal R and pieces of pancreas were taken for histochemieal evaluation. Serotonin fluorescence was evident in pancreatic islets from both groups as early as 15 min after 5-HTP injection, increasing through 60 min and remaining unaltered for up to 120 min. The fluorescence displayed by islet cells in animals treated with 5-HTP alone was consistently lower than that observed in animals treated with both nialamide and 5-HTP. As no change in fluorescence was apparent after 60 min of 5-HTP administration, this time period was chosen to perform the investigations described below.
Perfusion Technique
Male Sprague-Dawley rats weighing 275-325 g were fasted for 18-20 h, anaesthetized with sodium Amytal R (100mg/kg body weight) and the pancreas isolated in situ [29] . The basic buffer used for peffusion of the gland was supplemented Krebs-Ringer bicarbonate [2] , pH: 7.4, containing glucose 4.4 mmol/1 and Dextran T40, 60 mg/ml [12] . The integrity of this type of preparation has been established by electron microscopy [7, 8, 12, 26] . Following surgery, lasting approximately 20 min, the pancreases were perfused for a 15 min stabilization period followed by a period of 3 min to obtain the basal immunoreactive insulin (IRI) levels. The release of insulin was then stimulated by perfusion with either 16.6 mmol/1 glucose or 0.27 mmol/1 tolbutamide in the basic buffer. In selected groups, some of the pancreases were perfused with basic buffer to obtain the basal insulin release corresponding to the period of stimulation of test pancreases of the same groups. During the one hour of perfusion, flow rates ranged from 5 to 10 ml/min, and the perfusion pressure was 8.0 KPa. Insulin released into the perfusate was measured by radioimmunoassay. Table 1 summarises the protocol used in the glucose and tolbutamide experiments.
Experimental Design
The glucose stimulation experiments were composed of 7 groups (A-G). Groups A and B were controls. Groups C to G received one or more of the following drugs intraperitoneally: 5-HTP (50 mg/kg body weight), nialamide (5 mg/kg body weight) and RO 4-4602 (100 mg/kg body weight). Normal saline (9 g NaC1/1) was used as a drug substitute. Pancreatic biopsies were obtained from 4 animals in each group immediately before and also after isolation of the pancreas for perfusion, to see if surgical manipulation altered the induced serotonin fluorescence in pancreatic islet cells. The pancreases of 12 animals from groups A and B, and 6 animals from groups C to G were perfused with 16.6 mmol/1 glucose ( Table 2 ). In addition 3 animals from groups B and E were perfused with basic buffer to provide the basal levels of IRI release for control and for animals with elevated pancreatic islet cell serotonin. In all instances pancreatic biopsies were obtained at the end of perfusion for histochemical evaluation of change in the intraceUular serotonin content.
The tolbutamide stimulation experiments were composed of 2 groups (H and I) as shown in Table 1 . The pancreases of 5 saline control animals (Group H) and 5 animals treated with nialamide and 5-HTP (Group 1) were challenged with 0.27mmol/1 tolbutamide (Table 2) . Pancreatic biopsies for histochemical evaluation were taken following perfusion.
Data Calculation
The total insulin output is expressed as the integrated area under the insulin curve, which was 4 to 8 minutes (Z 8) for the first phase and 9 to 23 minutes (Z 23) for the second phase. Student's ttest was used to determine statistical significance for all comparisons between means. Differences were considered to be significant if p < 0.05. Results are presented as mean -+ SEM.
Results
The surgical procedure used to isolate the pancreas did not cause a detectable change of intesity of 5-HT formaldehyde-induced fluorescence ( Fig. 1 and 2 ) nor the blocking effect of RO 4-4602 (Fig. 3) . Fur- thermore, the apparent intensity of 5-HT formaldehyde-induced fluorescence (Fig. 4) and the basal IRI release (Fig. 5) were not modified by perfusion with the basic buffer.
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Controls (Groups A and B). Glucose elicited a typical
biphasic IRI secretion pattern in untreated (Group A) as well as in saline-injected (Group B) controls (Table 2 , Fig. 5 ). Since no significant difference was found between groups A and B, all treated groups were compared to saline controls for analysis of drug effects.
Test Animals (Groups C-G).
The biphasic pattern of glucose-mediated insulin release was observed in all instances. In Group C, treated with nialamide alone, the first peak was slightly higher ('/3) and shorter lived (3 min) than that obtained in Group B. Nevertheless, the total insulin release in each phase did not differ significantly from the corresponding phase in the saline controls (Table 2 and Fig. 5 ). Despite the elevated intracellular B cell serotonin in Group D (5-HTP alone) and Group E (nialamide and 5-HTP), neither the pattern nor the total amount of insulin released were found to be statistically different from that of the saline controls (Table 2 and Fig. 5 ).
The biphasic pattern was repeated in Group F (RO 4-4602, nialamide and 5-HTP) and Group G (RO 4-4602 alone). However, total insulin release was significantly reduced. In Group F, Phase I was reduced by 44.6% and Phase II by 41.6%. In group G Phase I was reduced by 34.1% and Phase II by 35.2%. Thus, the proportion of insulin release in Phase I and II was essentially the same as in Group B (Table 2 and Fig. 5) .
After glucose stimulation, islet cells of pancreases from Groups A, B, C, F and G were not fluorescent, whereas, those from Groups D (Fig. 7) and E (Fig. 6 ) exhibited a yellow fluorescence that was most intense in Group E. (Fig. 5) .
Nialamide and 5-HTP (Group I). D e s p i t e the ele-
v a t e d intracellular B cell serotonin in G r o u p I, the p a t t e r n and the total a m o u n t of insulin r e l e a s e d in It is worth noting that previous studies in our laboratory [9, 10, 13] have shown that serotonin inhibited insulin response to a glucose challenge when it was incorporated into the perfusion fluid of a similar preparation to that used in the present studies. From this and the present study, it is concluded that under our experimental conditions, elevated intracellular B cell serotonin does not have an effect on insulin release, whereas extracellular serotonin inhibits this B cell function. It is not clear where this inhibition is effected. Since some evidence [6, 18] indicates that serotonin penetrates cell membranes very poorly it is possible that extracellular serotonin acts on the cell membrane. However, these findings do not totally preclude penetration of some serotonin into B cells.
In view of the inhibitory action of extracellular serotonin on insulin release observed in our preparation, the question arises as to whether intracellular serotonin leakage from B cells, either physiologically [23] or through cell necrosis [2, 3] , may result in sufficiently high local concentration of this amine to affect insulin release in vitro. This consideration appears relevant in the interpretation of data obtained using incubation of tissues from animals pretreated with 5-HTP [18, 27, 36, 37] .
Species differences may also account for the disparity between our results and the inhibitory effect of elevated intracellular B cell serotonin observed in vitro by others [18, 27, 37] . In guinea pigs the B cell contains high levels of intracellular serotonin which does not appear to compromise cellular function [6, 24] . However, if intracellular B cell serotonin, which is not demonstrable in mice and rabbits, is elevated by the administration of 5-HTP, insulin release is abolished in mice [27] but only partially inhibited in rabbits [18, 36, 37] .
In studies in which the sulphonamide glibenclamide, or isoproterenol were used as the insulinogenic stimulus, pretreatment of mice with 5-HTP inhibited insulin release but did not affect the insulin response to a glucose callenge [28] . In our experiments the insulin release elicited by the sulphonamide tolbutamide was not inhibited after pretreatment with 5-HTP. The different insulin response to tolbutamide as compared to that of glibenclamide, in the presence of elevated intracellular B cell serotonin, may be the result of differences in the mechanisms of action of these two sulphonamides [21] or in experimental models.
The results of the perfusion experiments obtained when RO 4-4602 was administered to verify that the formaldehyde induced fluorescence was due to serotonin, were unexpected. The administration of RO 4-4602, which blocks the synthesis of 5-HT from 5-HTP, resulted in an inhibition of glucose mediated insulin release whether or not pretreatment with 5-HTP was carried out. The implication of this finding is not clear. A possible explanation is that RO 4-4602 exerts an independent pharmacological effect responsible for the observed inhibition of insulin release.
The above findings with our experimental model precludes the generalisation of the hypothesis that intracellular B cell serotonin acts as inhibitor of insulin release [18, 25] . Clearly, further work on the role of intracellular B cell serotonin is required. Such studies must include the rat together with other species so that the question of species differences in sensitivity to increased levels of intracellular B cell serotonin may be answered.
